Business Context and Reporting Period
Company: Compugen Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: March 2, 2026
Reporting Period: Fourth Quarter and Full Year 2025
This filing serves as a conduit for a press release (Exhibit 99.1) announcing the Company's financial results for the fourth quarter and full year ended December 31, 2025.
Key Financial Metrics
The provided text is a cover sheet for Form 6-K and does not contain specific financial data. The filing references a press release for details on:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide clear values for any financial metrics.
Material Changes
The filing text does not disclose specific material changes versus prior periods. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The provided text contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. These items are expected to be detailed in the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 2, 2026) for actual Q4 and Full Year 2025 financial figures.
- Verify the Company's cash position and runway given the biotech sector context.
- Check for any updates on clinical trial progress or partnership milestones mentioned in the press release.
- Confirm if the Company provided updated full-year 2026 guidance in the press release.